Escitalopram

Generic Name: Escitalopram

Brand Names: Cipralex, Lexapro

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁FN_₂O

CAS Number: 128196-01-0

Unique Ingredient Identifier: 4O4S742ANY

Background: Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic citalopram. It is used to restore serotonergic function in the treatment of depression and anxiety. Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with...

Indication: Escitalopram is indicated for the acute and maintenance treatment of major depressive disorder (MDD) in adults and pediatric patients 12 years old and older and for the acute treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years old and older. It is additionally indicated for symptomatic relief of obsessive-compulsive disor...

Associated Conditions: Anxiety, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD)

Associated Therapies: -

Clinical Trials

Serotonin and Motor Plasticity

Phase 4

Conditions: Healthy Controls

Interventions: Drug: Escitalopram
Drug: Placebo

First Posted Date: 2017-05-22

Last Posted Date: 2017-05-22

Lead Sponsor: Max Planck Institute for Human Cognitive and Brain Sciences

Target Recruit Count: 60

Registration Number: NCT03162185

Locations: 🇩🇪
Max Planck Institute for Cognition and Brain Sciences, Leipzig, Saxony, Germany

A Diagnosis and Treatment Optimization Study of Depression Based on the Neurological Mechanism of Reward System

Not Applicable

Conditions: Diagnosis and Treatment of Depression

Interventions: Drug: Duloxetine
Drug: Mirtazapine
Drug: Escitalopram

First Posted Date: 2017-05-11

Last Posted Date: 2019-12-13

Lead Sponsor: Peking University

Target Recruit Count: 120

Registration Number: NCT03148522

Locations: 🇨🇳
Yun-Ai SU, Beijing, Beijing, China

Effectiveness Study of Scopolamine Combined With Escitalopram in Patients With MDD

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Scopolamine
Drug: Escitalopram
Drug: Saline

First Posted Date: 2017-04-27

Last Posted Date: 2018-12-26

Lead Sponsor: Capital Medical University

Target Recruit Count: 66

Registration Number: NCT03131050

Locations: 🇨🇳
Beijing Anding Hospital, Beijing, China

Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders

Phase 4

Conditions: Anxiety Disorders
Major Depressive Disorder

Interventions: Drug: Escitalopram

First Posted Date: 2017-04-20

Last Posted Date: 2017-04-20

Lead Sponsor: Erzurum Regional Training & Research Hospital

Target Recruit Count: 60

Registration Number: NCT03122158

Locations: 🇹🇷
ErzurumRTRH, Erzurum, Palandöken, Turkey

Escitalopram for Agitation in Alzheimer's Disease

Phase 3

Active, not recruiting

Conditions: Dementia

Interventions: Drug: Placebo
Drug: Escitalopram

First Posted Date: 2017-04-11

Last Posted Date: 2024-02-29

Lead Sponsor: JHSPH Center for Clinical Trials

Target Recruit Count: 187

Registration Number: NCT03108846

Locations: 🇺🇸
Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸
Baylor AT&T Memory Center, Dallas, Texas, United States
🇺🇸
University of California Los Angeles/VA Greater Los Angeles Healthcare System, Los Angeles, California, United States

and more 26 locations

Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer

Phase 2

Terminated

Conditions: Addiction

Interventions: Drug: escitalopram
Drug: Moclobemide
Drug: Placebo - Cap

First Posted Date: 2017-01-05

Last Posted Date: 2019-07-24

Lead Sponsor: China Medical University Hospital

Target Recruit Count: 90

Registration Number: NCT03010761

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated

Conditions: Bipolar Disorder

First Posted Date: 2016-09-08

Last Posted Date: 2024-03-12

Lead Sponsor: University of New Mexico

Target Recruit Count: 1037352

Registration Number: NCT02893371

Locations: 🇺🇸
Christophe G Lambert, Albuquerque, New Mexico, United States

Treatment Outcome in Major Depressive Disorder

Phase 1

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Duloxetine
Drug: Escitalopram

First Posted Date: 2016-08-16

Last Posted Date: 2019-10-16

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 100

Registration Number: NCT02869035

Locations: 🇩🇰
Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark

Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety

Not Applicable

Completed

Conditions: Anxiety

Interventions: Other: Placebo
Drug: Escitalopram

First Posted Date: 2016-06-30

Last Posted Date: 2020-11-06

Lead Sponsor: University of Cincinnati

Target Recruit Count: 84

Registration Number: NCT02818751

Locations: 🇺🇸
University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, Cincinnati, Ohio, United States

Enhancement of Learning Associated Neural Plasticity by Selective Serotonin Reuptake Inhibitors

Phase 4

Conditions: Ssri
Neuronal Plasticity

Interventions: Drug: Placebo
Drug: Escitalopram
Other: 3xMR scan (fMRI, DTI, strucutral MRI)
Behavioral: Association learning paradigm
Behavioral: Association re-learning paradigm

First Posted Date: 2016-04-28

Last Posted Date: 2016-04-28

Lead Sponsor: Medical University of Vienna

Target Recruit Count: 80

Registration Number: NCT02753738

Locations: 🇦🇹
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy